New pill shrinks tumors in Drug-Resistant lung cancer patients
NCT ID NCT02442349
First seen Jan 11, 2026 · Last updated May 11, 2026 · Updated 20 times
Summary
This study tested a drug called AZD9291 (osimertinib) in 171 people from Asia Pacific with advanced non-small cell lung cancer that had a specific gene mutation (T790M) and had stopped responding to earlier treatments. The main goal was to see how many patients had their tumors shrink significantly. The drug is taken as a pill and works by targeting the mutated cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Kogarah, 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Woolloongabba, 4102, Australia
-
Research Site
Beijing, 100021, China
-
Research Site
Beijing, 100142, China
-
Research Site
Beijing, 100730, China
-
Research Site
Changchun, 130000, China
-
Research Site
Chengdu, 610041, China
-
Research Site
Chongqing, 400038, China
-
Research Site
Chongqing, 400042, China
-
Research Site
Fuzhou, 350014, China
-
Research Site
Haikou, 570311, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Hangzhou, 310006, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Harbin, 150049, China
-
Research Site
Jinan, 250117, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Shanghai, 200030, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, CN-200433, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Xi'an, 710032, China
-
Research Site
Xi'an, 710038, China
-
Research Site
Zhengzhou, 450008, China
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 6351, South Korea
Conditions
Explore the condition pages connected to this study.